Drug intelligence / Profile preview

fluconazole + caspofungin

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination antifungal therapy that pairs fluconazole, a triazole antifungal that inhibits fungal cell membrane synthesis, with caspofungin, an echinocandin that inhibits fungal cell wall biosynthesis. This combination leverages two distinct mechanisms of action and has been investigated for treating invasive candidiasis and candidemia, particularly in cases where monotherapy may be insufficient or in cases of drug resistance.

Targets

FKS (1,3-beta-D-glucan synthase component FKS1)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on fluconazole + caspofungin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + caspofungin.

Explore the full profile